Table 3 Univariate and multivariate analyses of progression-free survival in patients.

From: Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma

Characteristic

Univariate analysis

Multivariate analysis

HR

95% CI

P value

Exp(B)

95% CI

P value

Treatment

HAIC-Folfox/CisGem

0.463

0.277–0.773

0.005

0.405

0.213–0.768

0.006

Age (years old)

≥ 50/ < 50

1.807

1.064–3.068

0.009

1.449

0.805–2.605

0.216

Gender

Male/Female

0.665

0.384–1.153

0.969

0.418

0.220–0.749

0.008

ECOG

1/0

1.174

0.705–1.956

0.532

1.041

0.607–1.785

0.884

Child-Pugh classification

B/A

1.582

0.852–2.937

0.097

1.579

0.856–2.913

0.143

Liver cirrhosis

Present/Absence

1.800

0.855–3.793

0.053

1.933

0.993–3.764

0.053

Tumor number

Multiple/Single

1.749

1.060–3.035

0.044

1.681

0.861–3.281

0.128

Tumor size (cm)

≥ 5/ < 5

1.743

1.003–3.030

0.077

3.772

1.824–7.801

< 0.001

Lymph node metastasis

Present/Absence

1.987

1.158–3.409

0.028

3.013

1.416–6.412

0.004

CA199 (U/mL)

≥ 265/ < 265

1.342

0.805–2.238

0.251

1.216

0.703–2.106

0.484

CEA (ng/mL)

≥ 11.3/ < 11.3

0.818

0.490–1.365

0.432

0.995

0.579–1.710

0.987

NLR

≥ 2.83/ < 2.83

1.112

0.667–1.853

0.680

1.495

0.779–2.869

0.227

PLR

≥ 180/ < 180

0.874

0.525–1.458

0.601

1.291

0.735–2.267

0.374

  1. HAIC, hepatic arterial infusion chemotherapy; CisGem, cisplatin plus gemcitabine; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA-199, carbohydrate antigen 199; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet to lymphocyte ratio.
Back to article page